OR WAIT null SECS
Horiba has joined a consortium aimed at accelerating the development of process analytical technologies for cell and gene therapy manufacturing
Horiba, a manufacturer of measurement and analytical systems, has joined a consortium headed by the Cell and Gene Therapy Catapult (CGT Catapult) aimed at accelerating the development of process analytical technologies (PAT) for cell and gene therapy manufacturing, Horiba announced in a June 17, 2021 press release.
According to the press release, Horiba’s A-TEEM fluorescence technology, which has shown promise for fast quality control/quality assurance (QC/QA) of complex biological systems, will be assessed by the consortium as a way of reducing batch failures and manufacturing costs. The fluorescence technology powers the company’s Aqualog Industrial QC/QA Analyzer and is a “column-free” spectroscopic technique that measures absorbance, transmittance, and a fluorescence excitation emission matrix simultaneously.
“This consortium offers a unique blend of expertise and capability covering technology, pharmaceutics, therapy, and patient need. Our continued spirit of addressing new scientific challenges with an ever-evolving suite of core technologies comes together perfectly within this consortium, where the power of A-TEEM Molecular Fingerprinting will be truly explored and harnessed,” said Simon FitzGerald, technical manager at Horiba UK, in the press release. “Data and knowledge in context are key to progress—this consortium will deliver both, helping to bring advanced therapies to patients more quickly.”
Matthew Durdy, CEO at CGT Catapult added, in the press release, “The industry needs to make a giant leap in terms of analytical capability and the dynamic use of information to control and improve processes, product, and costs. The coming together of these leaders in the field is a very important first step towards achieving this.”